Gene Bridges Licenses Recombineering Technology to Daiichi Sankyo Co., Ltd.
27-Mar-2009
- Germany
“We are very pleased to welcome another major Japanese pharmaceutical company as a licensee of Red/ET,” commented Gary Stevens, CEO of Gene Bridges GmbH. “Recombineering is becoming the technology of choice in DNA engineering and with the help of Daiichi Sankyo Co., Ltd., we expect to gain further acceptance of Red/ET in industry and academia worldwide.”
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.